u/liv_dumitru

Sent a vial to Medutest because there was almost nothing on file for this compound. 98.9% against a claimed 98.5%, and I posted it because the log needs entries.

nothing containing this is approved as a standalone product

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

the appetite effect makes eating enough protein a logistics problem

three independent results beat thirty forum posts

Not convinced by that DEXA comparison. Different machine, different protocol, and the difference is inside the error.

I would not read one pharmacy’s cash price as the going rate. The spread is real.

Yes. Approval and coverage are separate, and this board conflates them in about half its threads.

Kept every form and reference number. When they had no record of a submission, I did.

Formulary criteria are revised, and plan renewal is a natural point at which a previously refused request may succeed without anything about the applicant changing.

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

three independent results beat thirty forum posts

Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.

Not convinced. A rejected claim at the counter is not a denied authorization and the next step differs.

a claim with no batch number is a marketing document

National regulatory approval establishes that a product may be sold. Whether any plan pays for it is a separate decision, and public drug plans are administered provincially.

Agreed on buying small first. The cost of a test is small next to the cost of committing to a supplier you have not checked.

lead time quoted at checkout is the number to hold them to

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later. Both are answerable in one email before you commit.

employer plans have their own criteria and their own appeals

This is why every thread here needs a province in it.

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.

Agreed, and the combination arms are where the interesting numbers actually live.

nothing on this board is a training or nutrition prescription

Cosigning that protein gets harder precisely when appetite drops. That is the actual difficulty and it is logistical.

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies. The first can be an administrative or quantity issue; the second is a determination you can appeal.

Six orders across two years from Homopeptide. Same packaging, same paperwork, same lead time. The most boring supplier relationship I have and I mean that as praise.

Mild pushback: a supplier with fewer entries is not worse, it is less sampled. Those are different claims and the table says so.

Strength retention is an imperfect but free longitudinal proxy: it is affected by neural factors and by being in a deficit, so it tracks tissue change loosely rather than exactly.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.

FFMI is a ratio and it moves when either term moves

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Correcting myself upthread: 8 months between scans, not the figure I gave.

This. Same machine, same protocol, or the DEXA comparison is measuring the scanner.

a denial letter names a criterion, that is your handle

Those criteria were revised at renewal, so the version quoted upthread is out of date.

Correcting myself: it was a quantity limit rather than a denial, which changes the whole process.